Embecta CORP

Embecta Corp. reported third quarter fiscal year 2026 financial results, showing a year-over-year revenue decrease of 8.1% to $271.7 million, though sequential revenue improved by $50 million.

Embecta Corp. has filed an amendment to its Form 8-K to include the audited financial statements of Owen Mumford Holdings Limited and pro forma financial information following its acquisition.

Embecta Corp. has finalized its acquisition of UK-based medical device innovator Owen Mumford Holdings Limited for an upfront cash payment and potential milestone-based payments.

Embecta Corp. reported a significant decline in second-quarter fiscal 2026 revenue and lowered its full-year financial guidance, citing challenges in its U.S. business and the impending acquisition of Owen Mumford.

Embecta Corp. announced the results of its 2026 Annual Meeting of Stockholders, with all director nominees elected and key proposals approved.

Embecta Corp. reported largely expected first-quarter fiscal 2026 financial results, with revenues of $261.2 million and a focus on strategic transformation and debt reduction.

Embecta Corp. reported a challenging third quarter for fiscal year 2026, with significant declines in revenue and gross profit, alongside increased costs, despite the strategic acquisition of Owen Mumford.

Embecta Corp. reported a revenue decrease for the second quarter of fiscal year 2026, alongside progress on its acquisition of Owen Mumford Holdings Limited.

Embecta Corp. reported a significant turnaround in net income for the first fiscal quarter of 2026, driven by substantial cost reductions and a strategic asset sale, despite flat revenues.

Embecta Corp. reports a significant increase in net income and operating profit for the third quarter, driven by cost reductions and strategic refocusing on its core diabetes care business.

Embecta Corp.'s Q2 2025 results reveal a revenue decrease, driven by volume declines and unfavorable foreign currency impacts, while the company continues to execute its restructuring plans.

Embecta Corp. reports a decrease in revenue and net income for the first quarter of fiscal year 2025, alongside the discontinuation of its patch pump program.

Embecta Corp. reports a strategic pivot away from its patch pump program, leading to increased net income despite a slight revenue decline in its 2025 fiscal year.

Embecta Corp.'s 2024 annual report highlights a strategic shift away from patch pump development, alongside a review of its financial performance and operational challenges.

Embecta Corp. has filed an amendment to its annual report to correct a minor error in the certifications related to internal control over financial reporting.

Devdatt Kurdikar, President and CEO and a Director of Embecta Corp., purchased 30,000 shares of common stock on August 12, 2026 for $4.70 per share.

Jacob Elguicze, SVP and CFO of Embecta Corp., purchased 20,000 shares of common stock on August 12, 2026 for $4.67 per share.

Jeffrey Z Mann, Pres, Pharm Svc&Prod Mgmt, CLO of Embecta Corp., purchased 20,000 shares of common stock on August 12, 2026 for $4.99 per share.

Robert J. Hombach, a Director of Embecta Corp., purchased 45,000 shares of common stock on August 12, 2026 for $4.97 per share.

Jean Casner, Chief Human Resources Officer of Embecta Corp., reported a transaction in 1,480 shares of common stock on August 9, 2026.

Embecta Corp. reports that VP, Chief Accounting Officer Anthony M. Roth acquired 30,000 shares of common stock on June 1, 2026.

Embecta Corp. issued a supplement to its proxy statement, addressing Institutional Shareholder Services' negative recommendation on a proposal to increase shares for its 2022 equity compensation plan.

Embecta Corp. has filed definitive additional materials for its proxy statement with the SEC.

Embecta Corp. reports strong fiscal year 2025 execution, exceeding adjusted operating margin targets, reducing debt, and advancing GLP-1 growth initiatives, while outlining strategic priorities for 2026.

Embecta Corp. has filed a definitive proxy statement with the Securities and Exchange Commission.

Embecta Corp. has announced its 2025 Annual Meeting of Stockholders and detailed its progress as an independent company, including strengthening its core business and investing for growth.

American Century Investment Management, Inc., along with its parent entities, has filed a Schedule 13G for Embecta Corp., reporting a minimal beneficial ownership of common stock.

BlackRock, Inc. has reported a beneficial ownership of 7.7% in Embecta Corp's common stock as of June 30, 2026.

River Road Asset Management, LLC has filed an amendment to its Schedule 13G, reporting zero beneficial ownership of Embecta Corp. common stock as of May 26, 2026.

Yacktman Asset Management LP and AMG Yacktman Fund report a combined beneficial ownership of 6.2% of Embecta Corp. common stock as of March 31, 2026.

American Century Investment Management and affiliated entities have reported a 5.8% beneficial ownership stake in Embecta Corp. common stock.

Vanguard Capital Management has filed a Schedule 13G reporting a 5.07% beneficial ownership stake in Embecta Corp.